PureTech Health plc American Depositary Shares - PRTC STOCK NEWS

PureTech Health has announced the publication of groundbreaking research demonstrating its Glyph technology, which enhances the oral bioavailability of buprenorphine by up to 20-fold. This technology utilizes lymphatic transport, which bypasses first-pass liver metabolism, significantly improving drug delivery for conditions that require effective opioid replacement therapy. Published in Frontiers in Pharmacology, this study highlights the potential of Glyph technology to revolutionize treatment approaches for various clinically validated drugs.

PureTech Health plans to publish its annual report and financial results on April 26, 2022, at 2:00 AM EDT. This report will detail the financial status as of December 31, 2021, and include the cash balance for Q1 2022. A conference call for discussion will occur on the same day at 9:00 AM EDT. The company aims to highlight progress in its pipeline and its commitment to environmental, social, and governance practices. PureTech is focused on developing treatments for serious diseases and has 25 therapeutic candidates in its pipeline.

PureTech Health announced the appointment of Sharon Barber-Lui as a non-executive director and chair of the Audit Committee. With over 20 years at Merck & Co., Barber-Lui brings extensive experience in finance and operations. She previously led U.S. Oncology Portfolio Market Strategy at Merck and currently serves at EQRx. Her expertise is expected to enhance the board's strategic vision, particularly for PureTech's advanced clinical programs.

PureTech Health announces Jon David as the new Chief Product Officer of its Founded Entity, Akili Interactive. With over 20 years in the gaming industry, David is expected to drive Akili's product pipeline, developing innovative cognitive treatments that feel like high-end entertainment. His leadership experience includes positions at Glu Mobile and PopCap Games, where he contributed to hit franchises. This strategic appointment underscores Akili's commitment to merging entertainment with therapeutic solutions as it prepares for its merger with Social Capital Suvretta Holdings Corp. I.

Gelesis Holdings Inc. (NYSE: GLS) announced promising preliminary results from its media campaign launched on January 31, 2022. Patient prescriptions for Plenity surged 3.5-fold within three weeks, accompanied by a threefold increase in web traffic. Gelesis anticipates $58 million in net revenue for 2022, reinforcing prior guidance. Approximately 4,700 new Plenity members joined weekly, with 70% being new to prescription weight management. Healthcare provider prescriptions doubled since the campaign's inception, showcasing a robust response to the digital-first strategy.

Vedanta Biosciences, a clinical-stage company based in Cambridge, Massachusetts, is pioneering new oral therapies derived from defined bacterial consortia. CEO Bernat Olle, Ph.D., will participate in a panel at the Chardan Metagenomics and Microbiome Medicines Summit on March 1, 2022. The panel, titled 'Great Debate - Is the Term “Microbiome” Drug Development Passé?', is set for 3:15 PM ET, followed by Olle's presentation at 4:30 PM ET. The company focuses on treating high-risk C. difficile infections, inflammatory bowel diseases, and more.

PureTech Health announced significant findings from a study on AKL-T01 (EndeavorRx) for children with ADHD. The research demonstrated enhanced brain activity related to attention, as evidenced by increased midline frontal theta (MFT) activity in EEG readings. This activity correlated with improved behavioral measures, as parents reported a decrease in inattention symptoms. The study, published in PLOS ONE, reinforces EndeavorRx's efficacy in targeting cognitive functions, paving the way for ongoing clinical development and commercialization.

PureTech Health (Nasdaq: PRTC) announces that its Founded Entity, Akili Interactive, has filed a Form S-4 registration with the SEC concerning its proposed business combination with Social Capital Suvretta Holdings Corp. I (Nasdaq: DNAA). This filing includes a preliminary proxy statement/prospectus with critical details about Akili. The merger is anticipated to conclude by mid-2022, leading to Akili being listed on Nasdaq under the new ticker symbol “AKLI.” The registration statement is available for review on the SEC's website.